This study utilized comprehensive bioinformatics methods to identify S100A9 and MYH2 as potential biomarkers from public databases and further validated their diagnostic value through serum sample analysis from COPD and NAFLD patients. This evidence concerns the gene S100A9 and metabolic dysfunction-associated steatotic liver disease.